This is a preview of subscription content, log in via an institution to check access.
Notes
Costs (1999 euros) included those associated with pharmacist time, healthcare professional contacts, medicines and hospitalization.
Costs (1997 values) include those associated with the vaccine and its administration, vaccine-related adverse events and education. Future benefits and costs were discounted at a rate of 4% per annum.
The studywas supported by a grant fromBoehringer Ingelheim Canada Ltd.
Costs included drug acquisition costs, dispensing fees and wholesale markup.
References
First independent anti-coagulation program launched. Dis Manage News 2001 Feb 25; 6: 4
Reference
DM milestone: HCFA to fund 15 Medicare projects. Dis Manage News 2001 Feb 10; 6: 1 & 5
Reference
Bernsten C, Björkman I, Caramona M, Crealey G, Pharmaceutical Care of the Elderly in Europe Research (PEER) Group, et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging 2001; 18(1): 63–77
Reference
Kaiser to expand CHF program with part-time nurses. Dis Manage News 2001 Feb 25; 6: 3 & 8
Reference
Rogowski JA, Horbar JD, Plsek PE, et al. Economic implications of neonatal intensive care unit collaborative quality improvement. Pediatrics 2001 Jan; 107: 23–9
Reference
Ginsberg GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 2001 Jan; 34: 92–9
Reference
Benayoun S, Ernst P, Suissa S. The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001 Jan; 119: 85–92
Rights and permissions
About this article
Cite this article
This Month’s News. Dis-Manage-Health-Outcomes 9, 289–291 (2001). https://doi.org/10.2165/00115677-200109050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00115677-200109050-00005